This filing is part of the company’s quarterly result. Read the full results article, with every figure explained →
Q2 profit rises 14%; buyback closed and promoter requests reviewed
ADVENZYMES · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 6.1 pts more than Nifty Microcap 250 and 6.7 pts more than its Biotechnology peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
The board approved unaudited results for September 2026. Consolidated Q2 revenue rose 3.9% to Rs191.71 crore; net profit rose 14.4% to Rs51.15 crore. Company-only Q2 profit rose 86.6% to Rs41.71 crore. Consolidated H1 profit was Rs89.74 crore; operating cash flow generated Rs64.71 crore. FY26 included a consolidated exceptional credit of Rs11.36 crore. Promoter reclassification requests were reviewed; the Rs69.70 crore buyback closed.
Q2 profits rose, but sales growth was modest. Buyback supports per-share value but uses cash; reclassification may widen public shareholding.
| Q2 FY27 | Q2 FY26 | Change | |
|---|---|---|---|
| Revenue | ₹214.5 Cr | ₹184.5 Cr | +16.2% |
| Operating profit | ₹60.04 Cr | ₹49.26 Cr | +21.9% |
| Profit after tax | ₹51.15 Cr | ₹44.73 Cr | +14.4% |
| EBITDA margin | 33.6% | 32.5% | +1.1 pp |
From the company's XBRL filing, not from the text above. Operating profit = profit before tax − exceptional items − other income. EBITDA = profit before tax + finance costs + depreciation − other income.